CAS: 107739-83-3

L-Noviose is a glycopeptide antibiotic that has been modified to increase its stability and bioavailability. The modifications have led to an increase in the activity of L-Noviose against gram-negative bacteria, including strains resistant to other antibiotics. This drug also inhibits bacterial biosynthesis by binding to the 30S ribosomal subunit and preventing the initiation of protein synthesis. L-Noviose is used clinically for the treatment of infections caused by Actinomyces, Enterobacter, Erysipelothrix, Haemophilus, Klebsiella, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. The biological function of L-Noviose is to inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit.